Edition:
United States

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

9,569JPY
17 Aug 2018
Change (% chg)

¥-166 (-1.71%)
Prev Close
¥9,735
Open
¥9,870
Day's High
¥9,879
Day's Low
¥9,551
Volume
1,022,500
Avg. Vol
1,399,750
52-wk High
¥11,490
52-wk Low
¥5,402

Select another date:

Fri, Aug 17 2018

Japan's Eisai sets price tag of about $17,000 on liver cancer drug (Aug. 16)

(This version of the August 16th story corrects to change drug price in headline, first bullet, paragraphs 1 and 3 after company corrects it to $16,970 from $15,970)

Japan's Eisai gains U.S. approval for liver cancer treatment

Aug 16 The U.S. Food and Drug Administration on Thursday approved https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm617185.htm a therapy by Japan's Eisai Co Ltd for previously untreated patients with a common form of liver cancer.

Eisai shares fall 18 pct after release of Alzheimer drug test details

TOKYO, July 26 Shares of Japanese drugmaker Eisai fell more than 18 percent on Thursday after the company and its partner Biogen Inc presented the details of their experimental drug on Alzheimer's disease. (Reporting by Hideyuki Sano; Editing by Stephen Coates)

Biogen/Eisai Alzheimer's drug cut cognitive decline by 30 pct -study

CHICAGO, July 25 Biogen Inc and partner Eisai Co Ltd said patients with early-stage Alzheimer's disease treated with their experimental drug BAN2401 experienced 30 percent less cognitive decline than patients who got a placebo in a highly anticipated midstage trial.

Biogen's Alzheimer's drug succeeds in mid-stage trial

July 5 Japanese drugmaker Eisai Co and Biogen Inc said on Thursday that the final analysis of a mid-stage trial of their Alzheimer's drug showed positive results for patients who received the highest dose.

BRIEF-Nichi-Iko Pharmaceutical says business and capital alliance with Eisai

* Says it forms business and capital alliance with Eisai Co Ltd

BRIEF-Anticancer Agent Lenvima Approved For Additional Indication Of Unresectable Hepatocellular Carcinoma In Japan

* ANTICANCER AGENT LENVIMA® (LENVATINIB MESYLATE) APPROVED FOR ADDITIONAL INDICATION OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) IN JAPAN, FIRST APPROVAL WORLDWIDE FOR LENVIMA FOR HCC

Eisai clinches Merck deal to develop and sell cancer drug, shares soar

(This March 8 story has been corrected to show in the 7th paragraph that Merck will pay, not receive, R&D reimbursement)

CORRECTED-UPDATE 3-Eisai clinches Merck deal to develop and sell cancer drug, shares soar

* Eisai's drug Lenvima already approved in dozens of countries

Select another date: